Antihypertensive drug treatment is capable of aggravating angina pectoris in hypertensive patients with coronary artery disease. The complication appears to be due to different hemodynamic mechanisms. Angina pectoris caused by hydralazine may result not only from a reduction in aortic perfusion pressure but also from increases in cardiac output and pulse rate which the drug produces. Coronary insufficiency, after the administration of hexamethonium, is usually associated with severe hypotension and results primarily from a reduction in aortic perfusion pressure. Hexamethonium was not found to prevent the anginal effects of hydralazine. Intravenous hydralazine is a sensitive test for coronary insufficiency but is not without untoward reactions.
IN recent years several potent blood-pressure-lowering drugs have become available for the treatment of arterial hypertension. Although extensive clinical trials with these hypotensive agents have proven their therapeutic effectiveness in reducing the level of blood pressure in certain hypertensive patients, some of them may produce adverse cardiovascular effects. In a long-term, careful study of a group of hypertensive patients, the oral administration of hydralazine (Apresoline) or ganglionic blocking agents (hexamethonium, pentolinium) was found occasionally to precipitate an attack of angina pectoris. In addition, an increased incidence of anginal complaints was observed during continuous chronic oral hydralazine therapy. The present study was undertaken, therefore, to determine the mechanisms by which such hypotensive agents might induce coronary insufficiency.1 PATIENTS ANI) METHODS Seventeen patients, 7 males and 10 females, ranging in age from 40 553 tensive cardiovascular disease and/or coronary artery disease were selected for the study. Regardless of the degree of abnormality of the resting electrocardiogram, all the patients were submitted to a modified "two-step" exercise tolerance test, which, in the absence of severe dyspnea or production of angina, required the arbitrary performance of 40 steps within three minutes. Of the 17 patients in the study, 11 had definitely abnormal electrocardiograms at rest. During the performance of the exercise tolerance test, 16 patients developed an abnormal pattern or further abnormalities of the electrocardiogram. In this group, only 13 patients complained simultaneously of anginal pain.
After 24 hours or more had elapsed, the patients were again studied before and after the administration of various hypotensive agents. An indwelling arterial needle was maintained in the brachial artery so that the arterial pressure could be measured continuously by a Sanborn electromanometer. Standard limb leads, 1, II and III, and a single, unipolar precordial lead V4, were recorded simultaneously with the arterial pressure, using a directwriting Sanborn Poly-Viso. After the control measurements of blood pressure, pulse rate, and resting electrocardiogram had been obtained, hydralazine, hexamethonium or both, were given, usually intravenously. Simultaneous blood pressure measurements and serial electrocardiograms were recorded continuously after the administration of the (Irug for a period up to two hours.
RESULTS
Trable 1 summarizes the effects of intravenous hydralazine. All 17 patients experienced chest pain, which, though not unlike their typical attacks of angina pectoris, was usually more severe and of longer duration. The pain began During the episode of chest pain the electrocardiogram showed noticeable changes in the T waves and depressions of the S-T segments. These electrocardiographic abnormalities were similar to those observed during an attack of angina induced by exercise. However, in contrast to intravenous hydralazine, exercise failed to produce angina pectoris in 4 of the 17 patients and to produce electrocardiographic changes in one of them.
The chest pain and electrocardiographic changes after intravenous hydralazine were usually associated with a reduction in the blood pressure and an increase in the heart rate. The average decrease in the systolic pressure was 27 mm. Hg Figure 2 shows the effects of the oral administration of 50 mg. of hydralazine in a patient with hypertensive cardiovascular disease with angina pectoris. Thirty minutes after the drug, the S-T segment in V4 had become depressed by 3 mm. without changes in the blood pressure and pulse rate. In this patient oral as well as intravenous hydralazine produced "ischemic" changes in the electrocardiogram but only after the intravenous administration did the patient develop chest pain. Figure 3 shows the electrocardiographic changes and the blood pressure and pulse rate responses to the simultaneous administration of l-norepinephrine and hydralazine. This experiment was designed to determine whether the maintenance of the arterial pressure by norepinephrine would prevent the anginal effects of hydralazine. The initial infusion of l-norepinephrine alone caused an increase in the arterial pressure but did not produce evidence of coronary insufficiency. Five minutes after the intravenous administration of hydralazine, while the arterial pressure was maintained above its control levels by the continuous infusion of l-norepinephrine, severe anginal pain developed with marked "ischemic" changes in the electrocardiogram. The of the coronary arteries was not the essential factor in the production of "coronary insufficiency" after hydralazine, but that the main factor was an increase in cardiac output associated with an increase in pulse rate. Figure 4 shows a coronary insufficiency pattern in the electrocardiogram during severe and prolonged hypotension after intravenous hexamethonium in a patient with hypertensive cardiovascular disease. After the slow intravenous injection of 10 mg. of hexamethonium, the blood pressure fell precipitously with the patient becoming semicomatose. Although the patient had no chest pain during the severe hypotensive episode, the reciprocal changes in the S-T segments in leads I and III suggested coronary insufficiency. The blood pressure then rose, but the electrocardiographic changes persisted and a clinical course suggesting myocardial infarction (posterior wall) developed. In the presence of coronary artery disease, profound hypotension undoubtedly enhanced the coronary insufficiency and produced myocardial infarction. Figure 5 shows an experiment designed to determine the importance of the level of blood pressure in producing coronary insufficiency after hexamethonium. Following the administration of a large dose of hexamethonium, no change occurred in either the arterial pressure or the electrocardiogram in the supine position. However, when the patient was tilted to the upright position, a profound fall in the blood pressure occurred, accompanied by angina pectoris and "ischemic" changes in the electrocardiogram. Following infusion of l-norepiniephrine, there was a return of the blood pressure, but not to control levels, while the chest pain disappeared and the electrocardiogram returned to the upright control pattern. It is rather likely that even in a patient with coronary artery disease a moderate reduction in blood pressure, per se, after hexamethonium might fail to produce coronary insufficiency whereas a critical reduction could cause this complication. Figure 6 is a tracing of one of four patients who developed angina pectoris after intravenous hydralazine though pretreated with hexamethonium. The control blood pressure was 220/120, pulse rate, 80 beats per minute, and the electrocardiogram showed a pattern of left ventricular hypertrophy with inversion of T waves in leads 1, 11 and V4. Following the administration of hexamethonium, no changes in the electrocardiogram occurred. Twenty-nine minutes later hydralazine was given intravenously and produced further and striking reductions in the arterial pressure without a change in the pulse rate. The cardiac output at this time increased slightly (table 2) . With these alterations the patient developed angina pectoris with uprighting of the T waves in leads I, II, and V4. When the diastolic blood pressure was below 70 mm. Hg, the T wave in V4 became upright but when it was above this level it again became inverted. Although hexamethonium partially blocked the pulse-rate-stimulating effect of hydralazine on the heart, the resulting drop in the blood pressure produced by the combination of the drugs probably became so critical that coronary blood flow decreased, precipitating coronary insufficiency and angina pectoris.
DIscussIoN
In the clinical treatment of arterial hypertension, oral hydralazine frequently aggravates angina pectoris. In addition, this hypotensive agent may induce an attack of angina pectoris in patients with previously unrecognized coronary artery disease. Hydralazine is more apt to produce angina pectoris when administered intravenously, as is attested by the fact that all patients in this study had an attack which was usually severe and long in duration after the drug. In fact, the drug produced angina more regularly than the standard exercise tolerance test employed.
Although the complication of angina pectoris, following the administration of hydralazine, is usually associated with a reduction in the aortic perfusion pressure and an increase in the pulse rate, it apparently does not necessarily depend on these alterations. An increase in cardiac output produced by the drug may also be an important factor which operates to precipitate coronary insufficiency. In patients who develop angina pectoris, without a change in the blood pressure and pulse rate, the increase in cardiac output and work of the heart may account for the coronary insufficiency. Although intravenous hydralazine has been reported to increase the coronary blood flow and the available oxygen per unit of left ventricular work in patients with essential hypertension,2 it probably does not produce these changes in patients with coronary artery disease who have relatively fixed coronary vascular systems.
There are suggestions in the literature that hexamethonium may block the angina-producing effect of hydralazine.3 However, no evidence was obtained in the present study to suggest that this might be the case. Even though hexamethonium may block the cardiac output and pulse rate responses to hydralazine, the resulting fall in blood pressure produced by this drug in combination with hydralazine may be so critical that coronary insufficiency is precipitated.
Ganglionic blocking agents (hexamethonium and pentolinium) occasionally produce angina pectoris in patients with coronary artery disease. However, this complication has never been observed by us without a lowering of the blood pressure. Therefore it appears that a reduction in blood pressure is the main hemodynamic factor that accounts for angina pectoris in patients receiving ganglionic blocking drugs. The importance of the aortic perfusion pressure has been illustrated in figures 4 solely from a reduction in the aortic perfusion pressure but also from increases in cardiac output and pulse rate.
(3) Coronary insufficiency after the administration of hexamethonium, on the other hand, results primarily from a reduction in the aortic perfusion pressure during the severe hypotension (especially postural hypotension) which this drug produces.
(4) Hexamethonium was found not to 1 lock the anginal effects of hydralazine.
(5) Intravenous hydralazine is a powerful agent capable of inducing subjective and ob- 
